The merger of Pfizer Inc. and Allergan PLC might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But, as former Speaker of the House Thomas "Tip" O’Neil once famously said about all politics being local, the more pressing concern for the ophthalmology community is whether the creation of the world’s largest pharmaceutical company will, in effect, rob the growing sector of one of its leaders.
The angst over Allergan isn’t new. For more than two years, a handful of players have made moves on Allergan,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
